{"query-id": "1", "query-text": "melanoma BRAF (V600E) 64-year-old male", "response": "BRAF (V600E) mutation is present in 95% of melanoma cases in patients over 60 years old, including the 64-year-old male in question.", "metadata": {"model": "llama"}}
{"query-id": "2", "query-text": "melanoma BRAF (V600K) 54-year-old male", "response": "BRAF (V600K) mutation, negative for NPM1, P53, and C- Kit, risk of developing melanoma in next 5 years is 5%.", "metadata": {"model": "llama"}}
{"query-id": "3", "query-text": "melanoma BRAF (V600R) 80-year-old male", "response": "BRAF mutation (V600R) in an 80-year-old male patient means he has a mutation in the BRAF gene that is commonly found in melanoma, a type of skin cancer. This mutation can lead to uncontrolled cell growth and may be responsible for the progression of the disease.", "metadata": {"model": "llama"}}
{"query-id": "4", "query-text": "melanoma BRAF (K601E) 38-year-old male", "response": "BRAF mutation (K601E) in a 38-year-old male with melanoma is associated with a higher risk of disease progression and poorer prognosis.", "metadata": {"model": "llama"}}
{"query-id": "5", "query-text": "melanoma BRAF (V600E), PTEN loss of function 57-year-old male", "response": "In a 57-year-old male with BRAF V600E mutation and PTEN loss of function, the prognosis is generally poor, with a high risk of recurrence and metastasis. Treatment options may include combination therapies with MEK inhibitors, immune checkpoint inhibitors, or chemotherapy, but the success of these treatments can vary depending on the individual patient and the specific characteristics of their cancer.", "metadata": {"model": "llama"}}
{"query-id": "6", "query-text": "melanoma BRAF (V600E), NRAS (Q61R) 67-year-old male", "response": "BRAF (V600E) and NRAS (Q61R) mutations are present in a 67-year-old male with melanoma. The BRAF mutation is a common driver mutation in melanoma, while the NRAS mutation is not as common. Treatment options may include targeted therapies such as vemurafenib or dabrafenib, or immunotherapy clinical trials.", "metadata": {"model": "llama"}}
{"query-id": "7", "query-text": "melanoma BRAF amplification 61-year-old male", "response": "Sure! Here's the answer:\nBRAF amplification is present in 61-year-old male with melanoma, indicating a high risk of disease progression and decreased response to immunotherapy.", "metadata": {"model": "llama"}}
{"query-id": "8", "query-text": "melanoma NRAS (Q61R) 63-year-old female", "response": "The NRAS Q61R mutation in a 63-year-old female patient is associated with a high risk of developing melanoma, particularly for those with a history of sun exposure.", "metadata": {"model": "llama"}}
{"query-id": "9", "query-text": "melanoma NRAS (Q61L) 34-year-old female", "response": "The 34-year-old female patient with NRAS (Q61L) melanoma has a high risk of disease progression due to the presence of a hotspot mutation in the NRAS gene, which is associated with aggressive disease and poor prognosis.", "metadata": {"model": "llama"}}
{"query-id": "10", "query-text": "melanoma KIT (L576P) 65-year-old female", "response": "The KIT (L576P) mutation in a 65-year-old female patient is associated with a poorer prognosis due to increased tumor aggression and reduced response to chemotherapy.", "metadata": {"model": "llama"}}
{"query-id": "11", "query-text": "melanoma KIT (L576P), KIT amplification 56-year-old female", "response": "The presence of the KIT (L576P) mutation and KIT amplification in a 56-year-old female patient with melanoma is indicative of a more aggressive tumor phenotype and poorer prognosis.", "metadata": {"model": "llama"}}
{"query-id": "12", "query-text": "melanoma KIT (K642E) 62-year-old female", "response": "The KIT (K642E) mutation in a 62-year-old female patient with melanoma indicates a more aggressive form of the disease. The mutation can lead to increased cell growth and proliferation, making it more difficult to treat.", "metadata": {"model": "llama"}}
{"query-id": "13", "query-text": "melanoma KIT (N822Y) 39-year-old female", "response": "Sure, here's my answer:\nMelanoma KIT (N822Y) is a non-mutational hotspot in the KIT gene that commonly occurs in familial and sporadic melanoma cases. It is found in approximately 10% of melanoma cases and is associated with a higher risk of advancing to more aggressive forms of melanoma.", "metadata": {"model": "llama"}}
{"query-id": "14", "query-text": "melanoma KIT amplification 66-year-old female", "response": "Amplification of the KIT gene has been found in approximately 15% of melanomas in 66-year-old females. KIT is a key player in melanoma development and progression.", "metadata": {"model": "llama"}}
{"query-id": "15", "query-text": "melanoma NF1 truncation 70-year-old male", "response": "Truncating mutations of NF1 gene in 70-year-old males are associated with increased risk of melanoma, particularly in sun-exposed areas such as the skin and eyes.", "metadata": {"model": "llama"}}
{"query-id": "16", "query-text": "melanoma NTRK1 rearrangement 60-year-old male", "response": "A 60-year-old male with a NTRK1 rearrangement is likely to have a specific type of melanoma, which is typically aggressive and has a poor prognosis. Treatment options may include chemotherapy, targeted therapy, or clinical trials.", "metadata": {"model": "llama"}}
{"query-id": "17", "query-text": "melanoma TP53 loss of function 72-year-old male", "response": "Loss of TP53 function in a 72-year-old male with melanoma is associated with a poorer prognosis. The tumor will be more aggressive and likely to spread to other parts of the body. Treatment options may be limited, and the patient may have a shorter overall survival compared to those with intact TP53 function.", "metadata": {"model": "llama"}}
{"query-id": "18", "query-text": "melanoma tumor cells with >50% membranous PD-L1 expression 48-year-old female", "response": "The 48-year-old female patient has melanoma tumor cells with >50% membranous PD-L1 expression, which suggests a stronger expression of the protein compared to other patients. This could potentially impact the efficacy of immunotherapy treatment, as PD-L1-targeting drugs may be less effective in this patient.", "metadata": {"model": "llama"}}
{"query-id": "19", "query-text": "melanoma tumor cells negative for PD-L1 expression 73-year-old male", "response": "Treatment options for a 73-year-old male with melanoma tumor cells that are negative for PD-L1 expression may include surgical removal of the primary tumor, chemotherapy, targeted therapy with BRAF inhibitors, or clinical trials of new treatments.", "metadata": {"model": "llama"}}
{"query-id": "20", "query-text": "melanoma high tumor mutational burden 86-year-old female", "response": "The high tumor mutational burden in the melanoma of the 86-year-old female patient suggests a more aggressive cancer type, with potential for resistance to immunotherapy.", "metadata": {"model": "llama"}}
{"query-id": "21", "query-text": "melanoma extensive tumor infiltrating lymphocytes 49-year-old male", "response": "Reports suggest that the male patient, 49 years old, has extensive tumor infiltration by lymphocytes, indicating a more aggressive form of melanoma.", "metadata": {"model": "llama"}}
{"query-id": "22", "query-text": "melanoma no tumor infiltrating lymphocytes 74-year-old female", "response": "A 74-year-old female patient with melanoma and no infiltrating lymphocytes has a poor prognosis. The lack of infiltrating lymphocytes suggests that the immune system may not be effectively attacking the cancer cells, leading to a more aggressive tumor growth and potential resistance to treatment.", "metadata": {"model": "llama"}}
{"query-id": "23", "query-text": "melanoma PTEN loss of function 68-year-old male", "response": "Loss of PTEN function in a 68-year-old male with melanoma can have a significant impact on prognosis. With no PTEN, the cancer cells are more aggressive and have a higher risk of spreading to other parts of the body, leading to a poorer prognosis.", "metadata": {"model": "llama"}}
{"query-id": "24", "query-text": "melanoma APC loss of function 47-year-old male", "response": "The loss of function of the APC gene in a 47-year-old male melanoma patient can lead to the uncontrolled growth and spread of cancer cells, which can be difficult to treat and may have a poorer prognosis compared to earlier ages at diagnosis.", "metadata": {"model": "llama"}}
{"query-id": "25", "query-text": "melanoma high serum LDH levels 69-year-old female", "response": "A 69-year-old female with melanoma and elevated serum LDH levels (69) has a higher probability of advanced cancer spread or metastasis. It is essential to determine the extent of disease through further diagnostic testing, such as imaging studies or biopsies, to guide treatment decisions.", "metadata": {"model": "llama"}}
{"query-id": "26", "query-text": "colorectal cancer NRAS 49-year-old male", "response": "The NF1 mutation in the NRAS gene is commonly found in colorectal cancer in 49-year-old males, with an incidence of approximately 1% to 3%.", "metadata": {"model": "llama"}}
{"query-id": "27", "query-text": "medullary thyroid carcinoma RET 45-year-old female", "response": "Medullary thyroid carcinoma (MTC) is a rare and aggressive type of thyroid cancer. Retrosternal presentation (RET) is a rare location for MTC, accounting for less than 1% of all thyroid cancers. A 45-year-old female with RET MTC may have good response to targeted therapy, such as octreotide, and may benefit from minimally invasive surgical techniques.", "metadata": {"model": "llama"}}
{"query-id": "28", "query-text": "neuroblastoma ALK 4-year-old female", "response": "Neuroblastoma is a rare and aggressive cancer in young children, typically diagnosed before age 5. ALK mutations are found in 5-10% of neuroblastomas, and are more common in infants than older children. Treatment typically involves a combination of surgery, chemotherapy, and radiation therapy, while clinical trials investigating new treatments and targeted therapies are ongoing. Prognosis depends on factors such as age, tumor location, and response to treatment.", "metadata": {"model": "llama"}}
{"query-id": "29", "query-text": "esophageal cancer EGFR 67-year-old male", "response": "ESG1 gene testing for esophageal cancer in a 67-year-old male patient with EGFR mutation may reveal a high risk of developing recurrent disease. Gene expression profiling can help identify potential therapeutic targets and predict response to therapy.", "metadata": {"model": "llama"}}
{"query-id": "30", "query-text": "lung cancer ROS1 71-year-old female", "response": "The 71-year-old female patient with lung cancer and ROS1 mutation is likely to benefit from targeted therapy with drugs like osimertel tozex (also known as rociletinib). These drugs specifically target cells with the ROS1 mutation, which is present in up to 10% of lung cancers.", "metadata": {"model": "llama"}}
{"query-id": "31", "query-text": "head and neck squamous cell carcinoma CDKN2A 64-year-old male", "response": "The 64-year-old male with head and neck squamous cell carcinoma may have a CDKN2A mutation, which is a common genetic alteration in this type of cancer. Testing for this mutation can help guide treatment decisions and prognosis.", "metadata": {"model": "llama"}}
{"query-id": "32", "query-text": "leukemia ABL1 4-year-old female", "response": "The ABL1 mutation is a common genetic abnormality found in children with acute lymphoblastic leukemia (ALL). In a 4-year-old female patient, the ABL1 mutation occurs in approximately 70% of cases. Treatment options for childhood ALL often involve chemotherapy and bone marrow transplantation.", "metadata": {"model": "llama"}}
{"query-id": "33", "query-text": "gastric cancer EGFR 60-year-old female", "response": "Based on the current evidence, EGFR mutation is a potential therapeutic target for gastric cancer in a 60-year-old female patient. Afatinib and osimertelini may be considered as options, particularly in combination with chemotherapy. However, the decision should be individualized and take into account the patient's overall health status, treatment history, and genetic profiling.", "metadata": {"model": "llama"}}
{"query-id": "34", "query-text": "sarcoma MDM2 78-year-old female", "response": "Based on the age and medical history provided, the recommended treatment approach for sarcoma in this patient would likely involve a combination of surgery, radiation therapy, and chemotherapy. The specific regimen would depend on the type and stage of the sarcoma, as well as the patient's overall health and preferences.", "metadata": {"model": "llama"}}
{"query-id": "35", "query-text": "breast cancer CDKN2A 73-year-old female", "response": "CDKN2A mutations are associated with an increased risk of breast cancer in 73-year-old females, particularly in the BRCA1 and BRCA2 genes. These mutations can greatly increase the risk of developing breast cancer, especially in older individuals.", "metadata": {"model": "llama"}}
{"query-id": "36", "query-text": "lung cancer ERBB2 49-year-old female", "response": "The ERBB2 gene is frequently mutated in lung cancer, particularly in non-small cell lung cancer (NSCLC). Approximately 30-40% of NSCLC cases have an ERBB2 mutation, which are more common in adenocarcinoma histology. In a 49-year-old female patient, the ERBB2 protein is overexpressed in 60-70% of cases.", "metadata": {"model": "llama"}}
{"query-id": "37", "query-text": "non-small cell carcinoma MET 68-year-old male", "response": "Non-small cell carcinoma (NSCLC) is the most common type of lung cancer in this 68-year-old male. The cancer is likely to have spread to lymph nodes and may have also metastasized to other parts of the body, such as the bones, liver, or adrenal gland. Further diagnostic tests and imaging studies will be necessary to determine the extent of the cancer and the best course of treatment.", "metadata": {"model": "llama"}}
{"query-id": "38", "query-text": "cholangiocarcinoma IDH1 50-year-old male", "response": "Cholangiocarcinoma is a rare and aggressive cancer that originates in the bile ducts. In a 50-year-old male patient, IDH1 mutation is present in approximately 40% of cases. The presence of IDH1 mutation can indicate a higher risk of disease progression and poorer prognosis.", "metadata": {"model": "llama"}}
{"query-id": "39", "query-text": "anaplastic large cell lymphoma ALK 18-year-old male", "response": "Anaplastic large cell lymphoma (ALCL) is a rare and aggressive type of non-Hodgkin lymphoma. In a 18-year-old male, symptoms may include swollen lymph nodes, fever, fatigue, and weight loss. Treatment typically involves chemotherapy and in some cases, bone marrow or stem cell transplantation. Prognosis varies depending on the stage and subtype of the disease, but overall survival rates are relatively low.", "metadata": {"model": "llama"}}
{"query-id": "40", "query-text": "breast cancer ERBB2 56-year-old female", "response": "The breast cancer ERBB2 status of a 56-year-old female is typically determined through genomic testing. The ERBB2 protein is a tumor suppressor gene that is frequently mutated in breast cancer. Testing can reveal activating mutations in the ERBB2 gene, which can aid in determining the most effective treatment options.", "metadata": {"model": "llama"}}
{"query-id": "41", "query-text": "papillary thyroid carcinoma NTRK1 46-year-old female", "response": "A papillary thyroid carcinoma is a type of thyroid cancer that arises in the thyroid gland. A 46-year-old female with papillary thyroid carcinoma would typically have a diagnosis of papillary thyroid carcinoma, and may require further testing and treatment, such as surgery and/or radioactive iodine therapy, to manage the cancer.", "metadata": {"model": "llama"}}
{"query-id": "42", "query-text": "glioblastoma CDK6 84-year-old male", "response": "Glioblastoma is a highly aggressive and malignant brain tumor. An 84-year-old male with glioblastoma would typically have a poor prognosis, with a median survival time of around 15 months after diagnosis. Treatment options may include surgery, radiation therapy, and chemotherapy, but outcome can be limited due to the tumor's resistance to these treatments.", "metadata": {"model": "llama"}}
{"query-id": "43", "query-text": "basal cell carcinoma PTCH1 56-year-old female", "response": "Basal cell carcinoma is a common skin cancer that typically affects the exterior. A 56-year-old woman with basal cell carcinoma may experience a painless but growing bump or lesion on her skin, often on the face, ears, or arms. Treatment may involve surgical excision, cryotherapy, or topical therapies.", "metadata": {"model": "llama"}}
{"query-id": "44", "query-text": "glioma BRAF 82-year-old male", "response": "The patient's glioma is likely a malignant brain tumor, specifically a glioblastoma, given the patient's age and the presence of a brain mass. BRAF is a gene that is commonly mutated in glioblastoma, and this mutation can lead to uncontrolled cell growth and tumor progression.", "metadata": {"model": "llama"}}
{"query-id": "45", "query-text": "thyroid cancer BRAF 40-year-old female", "response": "Sure! Here is a concise answer to your query:\nBRAF mutations are commonly detected in thyroid cancers, including papillary and follicular cancers. In general, BRAF mutations are more prevalent in well-differentiated thyroid cancers (e.g., papillary thyroid cancer) compared to poorly differentiated cancers (e.g., follicular thyroid cancer). The presence of a BRAF mutation can suggest a more aggressive tumor phenotype and may be associated with a higher risk of recurrence.", "metadata": {"model": "llama"}}
{"query-id": "46", "query-text": "lung cancer FGFR1 57-year-old male", "response": "The FGFR1 gene fusion in lung cancer is commonly found in non-small cell lung cancer (NSCLC) and is associated with resistance to chemotherapy and poor prognosis in 57-year-old males.", "metadata": {"model": "llama"}}
{"query-id": "47", "query-text": "prostate cancer PTEN 70-year-old male", "response": "Prostate cancer: PTEN mutation is present in 40-50% of cases in men aged 70 and older. PTEN mutations can lead to aggressive cancer, increasing the need for close monitoring and early treatment.", "metadata": {"model": "llama"}}
{"query-id": "48", "query-text": "adenoid cystic carcinoma KIT 58-year-old female", "response": "Adenoid cystic carcinoma is a rare and aggressive type of cancer that typically affects the face, particularly the nose, cheek, and orbital region. This patient, a 58-year-old female, has a primary tumor located in the left nasal cavity and has been diagnosed with adenoid cystic carcinoma based on clinical presentation and histopathological analysis.", "metadata": {"model": "llama"}}
{"query-id": "49", "query-text": "acute myeloid leukemia IDH1 1-year-old male", "response": "Sure, here is the answer to your query:\nAcute myeloid leukemia (AML) in a 1-year-old male is a rare and aggressive form of cancer. The IDH1 mutation is a common genetic alteration found in AML, particularly in the baby boomer generation. Treatment options may include chemotherapy, stem cell transplantation, or targeted therapy with drugs like midostaurin. Prognosis depends on the age of the patient, the severity of the disease, and the presence of certain genetic mutations.", "metadata": {"model": "llama"}}
{"query-id": "50", "query-text": "acute myeloid leukemia FLT3 13-year-old male", "response": "FLT3 mutations are found in approximately 30% of cases of acute myeloid leukemia (AML) in children, including 13-year-old males. These mutations can be targeted with specific inhibitors, such as midostaurin, which has shown promising results in clinical trials.", "metadata": {"model": "llama"}}
